$NKTR
NEKTAR THERAPEUTICS

2023 Q2 Form 10-Q Financial Statement

#000090670923000008 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $20.50M $21.59M $24.82M
YoY Change -5.03% -13.0% 4.97%
Cost Of Revenue $6.994M $7.060M $5.315M
YoY Change 36.74% 32.83% -7.66%
Gross Profit $13.51M $14.53M $19.51M
YoY Change -18.0% -25.49% 9.03%
Gross Profit Margin 65.88% 67.31% 78.59%
Selling, General & Admin $17.87M $21.08M $27.34M
YoY Change -16.67% -22.89% -13.76%
% of Gross Profit 132.31% 145.05% 140.15%
Research & Development $29.68M $30.47M $107.3M
YoY Change -30.55% -71.59% 12.18%
% of Gross Profit 219.78% 209.64% 549.82%
Depreciation & Amortization $2.166M $2.302M $3.730M
YoY Change -37.05% -38.28% 6.57%
% of Gross Profit 16.04% 15.84% 19.12%
Operating Expenses $29.68M $30.47M $107.3M
YoY Change -30.55% -71.59% 12.18%
Operating Profit -$50.60M -$134.7M -$116.6M
YoY Change -66.89% 15.57% 6.55%
Interest Expense -$570.0K -$2.371M $26.29M
YoY Change -90.7% -109.02%
% of Operating Profit
Other Income/Expense, Net -$570.0K -$2.371M $26.29M
YoY Change -90.7% -109.02% -295.01%
Pretax Income -$51.17M -$137.1M -$90.27M
YoY Change -67.81% 51.86% -26.54%
Income Tax -$47.00K -$63.00K $126.0K
% Of Pretax Income
Net Earnings -$51.12M -$137.0M -$90.39M
YoY Change -67.86% 51.58% -26.49%
Net Earnings / Revenue -249.39% -634.52% -364.16%
Basic Earnings Per Share -$0.27 -$0.73 -$0.49
Diluted Earnings Per Share -$0.27 -$0.73 -$0.49
COMMON SHARES
Basic Shares Outstanding 189.2M shares 189.2M shares 185.8M shares
Diluted Shares Outstanding 189.7M shares 188.9M shares 185.8M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $409.4M $456.8M $667.0M
YoY Change -33.89% -31.51% -35.7%
Cash & Equivalents $50.73M $76.96M $67.99M
Short-Term Investments $358.7M $379.9M $599.0M
Other Short-Term Assets $9.602M $11.01M $20.83M
YoY Change -50.11% -47.15% 32.08%
Inventory $20.69M $20.24M $15.38M
Prepaid Expenses
Receivables $1.335M $2.995M $30.22M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $441.1M $491.1M $733.5M
YoY Change -33.73% -33.05% -33.26%
LONG-TERM ASSETS
Property, Plant & Equipment $22.55M $27.08M $60.98M
YoY Change -43.32% -55.59% 4.22%
Goodwill $0.00 $0.00 $76.50M
YoY Change -100.0% -100.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $37.36M
YoY Change -61.12%
Other Assets $1.652M $1.406M $1.521M
YoY Change -26.05% -7.56% 5.99%
Total Long-Term Assets $53.22M $70.68M $290.7M
YoY Change -72.91% -75.68% -18.7%
TOTAL ASSETS
Total Short-Term Assets $441.1M $491.1M $733.5M
Total Long-Term Assets $53.22M $70.68M $290.7M
Total Assets $494.3M $561.7M $1.024B
YoY Change -42.66% -45.15% -29.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.619M $3.696M $12.62M
YoY Change -78.79% -70.71% -43.76%
Accrued Expenses $29.14M $37.41M $92.66M
YoY Change -68.54% -59.63% -8.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $50.69M $59.88M $105.3M
YoY Change -51.71% -43.12% -14.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.151M $6.479M $2.704M
YoY Change 147.64% 139.61% -34.53%
Total Long-Term Liabilities $5.151M $6.479M $2.704M
YoY Change 147.64% 139.61% -34.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.69M $59.88M $105.3M
Total Long-Term Liabilities $5.151M $6.479M $2.704M
Total Liabilities $297.3M $320.9M $416.2M
YoY Change -26.27% -22.91% -9.92%
SHAREHOLDERS EQUITY
Retained Earnings -$3.389B -$3.338B -$2.923B
YoY Change 9.96% 14.19% 20.2%
Common Stock $3.593B $3.585B $3.538B
YoY Change 1.22% 1.33% 3.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $197.0M $240.9M $607.9M
YoY Change
Total Liabilities & Shareholders Equity $494.3M $561.7M $1.024B
YoY Change -42.66% -45.15% -29.69%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$51.12M -$137.0M -$90.39M
YoY Change -67.86% 51.58% -26.49%
Depreciation, Depletion And Amortization $2.166M $2.302M $3.730M
YoY Change -37.05% -38.28% 6.57%
Cash From Operating Activities -$51.52M -$51.92M -$88.42M
YoY Change -31.3% -41.29% 14.71%
INVESTING ACTIVITIES
Capital Expenditures $162.0K $433.0K $4.203M
YoY Change -120.77% -89.7% 46.14%
Acquisitions
YoY Change
Other Investing Activities $25.33M $41.03M $134.5M
YoY Change -70.17% -69.49% 911.14%
Cash From Investing Activities $25.17M $40.60M $130.3M
YoY Change -70.09% -68.84% 1145.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.00K $0.00 $938.0K
YoY Change -96.15% -100.0% -94.75%
NET CHANGE
Cash From Operating Activities -51.52M -$51.92M -$88.42M
Cash From Investing Activities 25.17M $40.60M $130.3M
Cash From Financing Activities 18.00K $0.00 $938.0K
Net Change In Cash -26.33M -$11.27M $42.78M
YoY Change -373.69% -126.35% -187.67%
FREE CASH FLOW
Cash From Operating Activities -$51.52M -$51.92M -$88.42M
Capital Expenditures $162.0K $433.0K $4.203M
Free Cash Flow -$51.69M -$52.35M -$92.63M
YoY Change -30.36% -43.49% 15.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000906709
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-24006
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2023Q1 dei City Area Code
CityAreaCode
415
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
482-5300
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
NKTR
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
189235157 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76955000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
379872000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2995000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5981000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
20235000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
11009000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
15808000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
491066000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
545968000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27084000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42187000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53435000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
0 usd
CY2022Q4 us-gaap Goodwill
Goodwill
76501000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1406000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2245000 usd
CY2023Q1 us-gaap Assets
Assets
561743000 usd
CY2022Q4 us-gaap Assets
Assets
710600000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3696000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12980000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37410000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18773000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18667000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
59879000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
68204000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
109389000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112829000 usd
CY2023Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
145131000 usd
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
155378000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6479000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7551000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
320878000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
343962000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
189235000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188560000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3584738000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3574719000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5681000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6907000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3338211000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3201193000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
561743000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
710600000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21594000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24822000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7060000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5315000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30469000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107253000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21081000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27339000 usd
CY2023Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
21193000 usd
CY2022Q1 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1475000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
156304000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
141382000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-134710000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-116560000 usd
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2022Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
CY2023Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6405000 usd
CY2022Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
7529000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4034000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
395000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2371000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26293000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-137081000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90267000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-63000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
126000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-137018000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-90393000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188875000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188875000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185848000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185848000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-137018000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-90393000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1087000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2091000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
139000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-284000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1226000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2375000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92768000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
679508000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20961000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92768000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
607889000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10019000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-137018000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-90393000 usd
CY2023Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
16861000 usd
CY2022Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
17561000 usd
CY2023Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6405000 usd
CY2022Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
7529000 usd
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2022Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
33427000 usd
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4951000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10019000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20961000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2302000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3730000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1812000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000 usd
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3129000 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1276000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2986000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7728000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1033000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-422000 usd
CY2023Q1 nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
1786000 usd
CY2022Q1 nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
-1787000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-5591000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2864000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8920000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2998000 usd
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1640000 usd
CY2022Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
14167000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51915000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88424000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107012000 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93493000 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
148043000 usd
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
227974000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
433000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4203000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40598000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130278000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
188000 usd
CY2023Q1 us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
0 usd
CY2022Q1 us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
750000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
938000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-17000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11272000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42775000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88227000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25218000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76955000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67993000 usd
CY2023Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
456800000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div>
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
456827000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76955000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88227000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
379872000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
416750000 usd
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000 usd
CY2023Q1 us-gaap Cash
Cash
26040000 usd
CY2022Q4 us-gaap Cash
Cash
8798000 usd
CY2023Q1 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
456827000 usd
CY2022Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
504977000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1800000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2234000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2575000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
13167000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10749000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4834000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5878000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
20235000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19202000 usd
CY2023Q1 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
136926000 usd
CY2022Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
154652000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
110653000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
124731000 usd
CY2023Q1 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
26273000 usd
CY2022Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
29921000 usd
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
811000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2530000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27084000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32451000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
76501000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
0 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14888000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9582000 usd
CY2023Q1 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
7739000 usd
CY2022Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
12262000 usd
CY2023Q1 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
3495000 usd
CY2022Q4 nktr Liability To Collaboration Partners Current
LiabilityToCollaborationPartnersCurrent
3808000 usd
CY2023Q1 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3461000 usd
CY2022Q4 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3902000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7827000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7003000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37410000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36557000 usd
CY2022Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
155378000 usd
CY2023Q1 nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
16861000 usd
CY2023Q1 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6405000 usd
CY2023Q1 nktr Liabilities On Sale Of Future Royalties Amortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
209000 usd
CY2023Q1 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
145131000 usd
CY2023Q1 us-gaap Litigation Reserve
LitigationReserve
0 usd
CY2022Q4 us-gaap Litigation Reserve
LitigationReserve
0 usd
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
11500000 usd
CY2023Q1 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000 usd
CY2023Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
11500000 usd
CY2023Q1 nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1700000 usd
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13200000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10019000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20961000 usd

Files In Submission

Name View Source Status
0000906709-23-000008-index-headers.html Edgar Link pending
0000906709-23-000008-index.html Edgar Link pending
0000906709-23-000008.txt Edgar Link pending
0000906709-23-000008-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
imagea.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20230331.htm Edgar Link pending
nktr-20230331.xsd Edgar Link pending
nktr2023-03x31xexx1011.htm Edgar Link pending
nktr2023-03x31xexx311.htm Edgar Link pending
nktr2023-03x31xexx312.htm Edgar Link pending
nktr2023-03x31xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
nktr-20230331_cal.xml Edgar Link unprocessable
nktr-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nktr-20230331_lab.xml Edgar Link unprocessable
nktr-20230331_pre.xml Edgar Link unprocessable
nktr-20230331_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending